培美曲塞联合奥沙利铂用于非小细胞肺癌术前新辅助化疗的效果分析

The clinical effects analysis of preoperative neoadjuvant chemotherapy by pemetrexed combined with oxaliplatin for non-small cell lung cancer

目的探讨培美曲塞联合奥沙利铂用于非小细胞肺癌术前新辅助化疗的效果。方法非小细胞肺癌患者200例根据治疗方法的不同分为治疗组(100例)和对照组(100例),两组患者均采用常规手术治疗,治疗组患者在此基础上采用培美曲塞联合奥沙利铂的术前新辅助化疗。结果治疗组患者总有效率为77.0%,对照组总有效率为54.0%,两组对比差异有统计学意义(P<0.05)。两组患者常见的不良反应为胃肠道反应、骨髓抑制、脱发及皮疹等,差异无统计学意义(P>0.05)。治疗组患者6个月生存率与对照组比较,差异无统计学意义(P>0.05),但1年生存率明显高于对照组,差异有统计学意义(P<0.05)。结论培美曲塞联合奥沙利铂用于非小细胞肺癌术前新辅助化疗效果肯定,不良反应少且可以耐受,可提高生存率,值得推广应用。

Objective To investigate the clinical effects of neoadjuvant chemotherapy by pemetrexed plus oxaliplatin for non-small cell lung cancer before surgery. Methods 200 cases of non-small cell lung cancer were equally divided into the treatment group （ 100 patients） and the control group （ 100 patients）. Both groups were given conventional surgical treatmenst, but the treatment group received addutional neoadjuvant chemotherapy by pemetrexed plus oxaliplatin. Results The total effective rate of the treatment group was 77.0%, that of the control group 54.0%. The difference was significant （ P 〈 0. 05 ）. Toxicity effects included gastrointestinal reactions, bone marrow suppression, hair loss and skin rash. There was no significant difference between two groups （ P 〉 0. 05 ）. the 6 months survival rate of the treatment group compared to the control group had no significant difference （ P 〉 0.05 ）, but the 1 -year survival rate of the treatment group was significantly higher than that in the control group （ P 〈 0. 05 ）. Conclusions Neoadjuvant chemotherapy by pemetrexed plus oxaliplatin for non-small cell lung cancer has better effect and less toxicity which can be tolerated, so as to improve survival rate, It derserve further application.